| 1 |
Santos AACD, Rodrigues LE, Alecrim-zeza AL, de Araújo Ferreira L, Trettel CDS, Gimenes GM, Silva AFD, Sousa-filho CPB, Serdan TDA, Levada-pires AC, Hatanaka E, Borges FT, de Barros MP, Cury-boaventura MF, Bertolini GL, Cassolla P, Marzuca-nassr GN, Vitzel KF, Pithon-curi TC, Masi LN, Curi R, Gorjao R, Hirabara SM. Molecular and cellular mechanisms involved in tissue-specific metabolic modulation by SARS-CoV-2. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.1037467] [Reference Citation Analysis]
|
| 2 |
Kumar R, Kumar V, Arya R, Anand U, Priyadarshi RN. Association of COVID-19 with hepatic metabolic dysfunction. World J Virol 2022; 11(5): 237-251 [DOI: 10.5501/wjv.v11.i5.237] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Koufakis T, Doumas M, Zebekakis P, Kotsa K. Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces? Expert Opin Pharmacother 2022. [PMID: 35962542 DOI: 10.1080/14656566.2022.2113385] [Reference Citation Analysis]
|
| 4 |
Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacol Res 2022;181:106261. [PMID: 35588918 DOI: 10.1016/j.phrs.2022.106261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Ushigome E, Hamaguchi M, Sudo K, Kitagawa N, Kondo Y, Imai D, Hattori T, Matsui T, Yamazaki M, Sawa T, Fukui M. Impact of untreated diabetes and COVID-19-related diabetes on severe COVID-19. Heliyon 2022;8:e08801. [PMID: 35079646 DOI: 10.1016/j.heliyon.2022.e08801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Koufakis T, Maltese G, Metallidis S, Zebekakis P, Kotsa K. Looking deeper into the findings of DARE-19: Failure or an open door to future success? Pharmacol Res 2021;173:105872. [PMID: 34487851 DOI: 10.1016/j.phrs.2021.105872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 7 |
Koufakis T, Metallidis S, Zebekakis P, Kotsa K. Intestinal SGLT1 as a therapeutic target in COVID-19-related diabetes: A "two-edged sword" hypothesis. Br J Clin Pharmacol 2021. [PMID: 33684969 DOI: 10.1111/bcp.14800] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
